CDC Independent Valuation - 30 September 2024

The 30 September 2024 independent valuation of Infratil’s investment in CDC shows an increase of A$287 million over the three months since the 30 June 2024 valuation. This implies that Infratil’s 48.17% investment in CDC is now valued at between A$4,386 million and A$5,248 million (with a midpoint of A$4,811 million), up from A$4,159 million to A$4,940 million (with a midpoint of A$4,524 million) at the end of June 2024. The increase in valuation reflects a continued high level of interest from customers, resulting in the advancement of customer discussions for capacity across all regions in which CDC operates and acceleration in construction and development activity. CDC’s forecast build capacity to FY2034 has increased 409MW since June 2024, primarily reflecting increased demand signals for capacity in Melbourne and Auckland. This increase in future build capacity reflects both an upsizing of current planned sites, as well as the introduction of future sites expected to come online over the latter part of the 10-year capacity forecast outlined in the table below. The overall operating and under construction capacity remains unchanged since June 2024, with CDC’s first data centre development in Melbourne (Brooklyn 1) performing well in its first full quarter of operations. Positive progress continues to be made in relation to the 400MW+ of capacity under advanced negotiations (communicated at the Infratil equity raising in June). Region Status Build Capacity (MW) to FY34, as at 30 June 2024 Build Capacity (MW) to FY34, as at 30 September 2024 Canberra Operating 117 117 Sydney Operating 123 123 Melbourne Operating 34 34 Auckland Operating 28 28 Total Operating Capacity 302 302 Canberra Under Construction 39 39 Sydney Under Construction 158 158 Melbourne Under Construction 121 121 Auckland Under Construction 70 70 Total Under Construction Capacity 388 388 Canberra Future Build 90 93 Sydney Future Build 872 879 Melbourne Future Build 157 472 Australian Expansion Future Build 36 36 Auckland Future Build 42 126 Total Future Build Capacity 1,197 1,606 Total Capacity 1,887 2,296 The blended cost of equity used in the valuation has increased from 11.50% to 12.40% between June and September 2024. This reflects an increase in the valuer’s estimated asset-specific risk premium driven by an expansion of the development pipeline. An increase in the asset beta has also contributed to the increase in the cost of equity, reflecting general movement in the asset betas of listed peers since June 2024. The risk-free rate has remained constant at 3.90%. This valuation reflects a minor increase in the funding estimate provided as part of Infratil’s June 2024 equity raising, with Infratil’s pro-rata share of equity contributions to CDC assumed to be approximately A$700 million (an increase of $100 million) over the next two to three years. The increase in total equity contributions is driven by the growth in CDC’s planned pipeline highlighted earlier in this announcement. CDC intends to continue accessing a range of debt markets to provide further funding for its expanded development pipeline. Enquiries should be directed to: Mark Flesher Investor Relations Email: mark.flesher@infratil.com Appendix 1 – Independent Valuation Summary 30 September 2024 Valuation Methodology 30 June 2024 30 September 2024 Primary valuation methodology DCF using FCFE (with a cross check to comparable companies and precedent transactions), surplus and underutilised land at cost Forecast period 15 years (2039) 30 years (2055) Enterprise value A$12,723 million A$13,441 million Equity value A$9,376 million (IFT share: A$4,524 million) A$9,987 million (IFT share: A$4,811 million) Net debt 1 A$3,347 million A$3,454 million Key Valuation Assumptions Risk free rate 3.90% 3.90% Asset beta 0.55 0.575 Cost of equity (blended rate) reflecting the assessed risk of the spectrum of CDC’s activity, from operating data centres with contracted revenues through to developing projects without contracted revenues. 11.50% 12.40% Terminal growth rate 2.5% 2.5% Long term EBITDA margin 85% (2039) 85% (2039); 83% (2055) Capex Future capex reflects CDC’s published development pipeline Valuation assumes no development beyond 2033 Valuation assumes no development beyond 2040 1 Net debt includes accrued RMS payments to management shareholders